Full-Time
Ultrasound Transducer Engineer
Updated on 9/10/2026
iSono Health
11-50 employees
Portable automated 3D breast ultrasound system
Compensation Overview
$125k - $155k/yr
Sunnyvale, CA, USA
In Person
Bachelor's, Master's
 Biology & Biotech (1) |
|---|
Get referred to iSono Health
See people who can refer or advise you
- A Bachelor of Science or Master of Science degree in Electrical Engineering, Biomedical Engineering, or a related field is required.
- At least 3 years of hands-on experience with ultrasound transducers or similar hardware systems is required.
- Strong experience in transducer characterization and testing is required.
- A solid understanding of ultrasound physics and beamforming fundamentals is required.
- Experience with electrical engineering concepts, signal chains, and hardware interfacing is required.
- Hands-on experience with laboratory equipment, including oscilloscopes, function generators, and measurement systems, is required.
- The ability to troubleshoot and debug system-level hardware and signal issues is required.
- Strong documentation and communication skills are required.
- Perform detailed acoustic and electrical characterization of ultrasound transducers.
- Design and execute test protocols using laboratory equipment.
- Analyze performance across operating conditions and identify opportunities for improvement.
- Work with external vendors and internal teams to evaluate and refine transducer performance.
- Own the electrical interfacing and signal chain associated with the transducer.
- Support debugging and optimization of signal integrity, noise, and system-level performance.
- Collaborate with hardware engineers on front-end electronics, data acquisition, and system integration.
- Contribute to design decisions that impact transducer performance within the full system.
- Work closely with the imaging scientist to understand how transducer characteristics affect image quality.
- Support beamforming and system parameter tuning from a hardware and signal perspective.
- Assist in troubleshooting imaging artifacts and performance issues tied to transducer behavior.
- Develop and maintain test and validation frameworks for transducer and imaging performance.
- Support verification and validation activities aligned with product and regulatory requirements.
- Document test methods, results, and conclusions for internal use and regulatory submissions.
- Partner with manufacturing and cross-functional teams to ensure successful design transfer to production.
- Investigate field and manufacturing issues using root-cause analysis and implement improvements.
- Contribute to product reliability, performance consistency, and cost optimization efforts.
- Work closely with imaging, software, quality assurance, and product teams to ensure cohesive system development.
- Communicate findings clearly and contribute to technical decision-making across teams.
- Support alignment with design control processes and quality standards.
- Experience working with ultrasound vendors or custom transducer development.
- Familiarity with acoustic measurement setups, including hydrophone testing and phantom studies.
- Exposure to MATLAB and Python for data analysis and visualization.
- Experience in medical device development, including design controls, verification and validation, and regulatory documentation.
- Experience in fast-paced or startup environments.
Isono Health makes a portable, automated 3D breast ultrasound system called ATUSA. It lets clinicians screen and monitor breast cancer without needing a trained ultrasound operator by combining a wearable accessory, a 3D scanner, a Windows app for real-time image display, and a secure web app for remote viewing. The system standardizes and speeds up whole-breast image acquisition and analysis, reportedly delivering results 15-20 times faster than manual probing. It targets high-risk patients who need personalized, accessible monitoring and markets to hospitals, clinics, and individual healthcare providers. Revenue comes from selling the ATUSA hardware and software, with potential additional income from subscription-based remote monitoring services. Compared with traditional ultrasound options, ATUSA emphasizes automation, portability, standardized imaging, and remote data access, reducing dependence on operator expertise and enabling broader screening and follow-up.
Company Size
11-50
Company Stage
Seed
Total Funding
$6.6M
Headquarters
San Francisco, California
Founded
2014
Get referred to iSono Health
See people who can refer or advise you
Simplify's Take
What believers are saying
- The 2026 commercial launch and paying clinics create early revenue validation.
- Abdul Latif Jameel Health distribution expands ATUSA across Nigeria and other Global South markets.
- NIH-backed AUDIBLE data can unlock broader FDA submissions and radiology partnerships.
What critics are saying
- Reimbursement for automated breast ultrasound remains unproven, delaying hospital adoption through 2027.
- The company has only nine employees, limiting sales, regulatory, and clinical execution.
- If AUDIBLE underperforms, ATUSA loses its operator-independent differentiation and Series A story.
What makes iSono Health unique
- ATUSA received FDA clearance on 2025-09-03 for portable whole-breast ultrasound.
- Its wearable, automated workflow scans each breast in about two minutes.
- AUDIBLE enrolled up to 800 patients at UC Davis in 2026, strengthening evidence.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Flexible Work Hours
Growth & Insights and Company News
6 month growth
↑ 4%1 year growth
↑ 4%2 year growth
↑ 8%iSono Health launches world's first wearable, automated, portable, fda-cleared breast ultrasound platform. iSono Health, a pioneer in women's health imaging, has announced the commercial launch of ATUSA, an FDA-cleared, wearable, and automated 3D quantitative breast ultrasound platform. Designed to bring high-quality imaging into everyday clinics, ATUSA unlocks the $14 billion U.S. breast imaging market by eliminating reliance on hard-to-find skilled sonographers and cost-prohibitive equipment. A graduate of Y Combinator and the Texas Medical Center Accelerator, iSono Health has gained significant industry recognition, including the HLTH 2025 Rising Star (Diagnostics) and the WISH 2024 Global Awards. Building on this commercial launch, the company is also announcing the opening of its Series A financing at its inaugural Next Horizon Summit during JPMorgan Week to accelerate global deployments and advance its AI-driven "sentient partner" roadmap toward machine-as-the-expert breast imaging robotics. Standard mammography often fails the 40 million American women with dense breast tissue, creating a massive diagnostic gap where cancers can remain hidden. It can be a painful experience and often exposes women to unnecessary X-ray radiation, leaving those of reproductive age with limited screening options. ATUSA can fundamentally change the economics and accessibility of breast health through a unique fusion of wearable hardware and cloud-based intelligence: * Automated Scanning: Utilizing a wearable, hands-free accessory, ATUSA(TM) captures full 3D volumes in approximately two minutes per breast, roughly 10x faster than manual handheld ultrasound. This ensures consistent and repeatable images are generated, regardless of the operator's skill level. * Point-of-Care Integration: The system empowers OB/GYNs and primary care providers to offer specialist-level imaging directly in their offices, generating standardized 3D whole-breast visualization directly at the point of care. * USaaS Business Model: A scalable "Ultrasound-as-a-Service" model that combines the wearable hardware, cloud-based AI, and consumables to create a recurring revenue stream while lowering the barrier to entry for local clinics. * Advanced "Sentient" AI: iSono Health is working to move beyond simple detection toward a "sentient partner" model, where the system utilizes acoustic biomarkers and machine learning to sense patient-specific needs and provide real-time diagnostic support. "ATUSA(TM) is a system-wide upgrade for women's breast health," said Neda Razavi, CEO of iSono Health. "We are putting the power of a world-class radiology suite into the hands of local clinicians, replacing slow, manual workflows with real-time diagnostic images at the point of care." A core pillar of the ATUSA launch is the initiation of the AUDIBLE Study, a pivotal multicenter clinical trial supported by a grant from the National Institutes of Health (NIH). This 800-patient study is designed to evaluate the diagnostic performance of the ATUSA(TM) platform compared to traditional mammography and MRI. * AI Products Validation: Assessing the performance of iSono's machine-learning algorithms in identifying and classifying abnormal masses. * Operator Independence: Proving that the automated, wearable hardware provides consistent, high-fidelity 3D volumes regardless of the user's clinical background. The study is being conducted at leading medical institutions, including UC Davis, Veda Trials (Axia Women's Health), and City of Hope, ensuring the technology is vetted by the nation's top oncology and radiology experts. "What we need are imaging solutions that are easy to use, require minimal training, and can be brought directly into communities," said Dr. John R. Scheel, M.D., Ph.D., M.P.H., Vice Chair of Global Health, Department of Radiology at Vanderbilt University Medical Center. "Wearable, operator-independent ultrasound technologies have the potential to dramatically improve access, speed, and accuracy, especially for women with dense breasts."
iSono Health has launched ATUSA, the world's first FDA-cleared wearable, automated breast ultrasound platform, and is opening its Series A funding round during JPMorgan Healthcare Week. The company aims to address the $14 billion US breast imaging market by eliminating dependence on skilled sonographers and expensive equipment. ATUSA captures full 3D breast volumes in approximately two minutes per breast through automated scanning, roughly 10 times faster than manual ultrasound. The system enables primary care providers and OB/GYNs to offer specialist-level imaging directly in their offices through an "Ultrasound-as-a-Service" model. iSono Health has raised $14.7 million to date, including a recent $3 million seed round led by Draper Associates and Transform VC, plus $3.7 million in non-dilutive funding from NIH, NSF and NCI. The company is conducting the 800-patient AUDIBLE Study across leading medical institutions.
iSono Health, a company providing 3D ultrasound imaging devices for breast cancer monitoring, has secured $3 million in seed funding. The device allows women to perform monthly breast checks at home without radiation, taking only two minutes per session.
iSono Health will use the new funding to further develop its ATUSA automated 3D breast ultrasound system, expand clinical validation through NIH-funded studies, and scale its technology to make preventive breast exams faster, more accessible, and widely available globally.
JSK Investments Group has funded US startup iSono Health, creator of the ATUSA™, a 3D breast ultrasound system. The funding round, led by JSK, will help iSono Health expand its system's reach, enhance AI image analysis, and support NIH-backed studies. iSono Health secured approximately $5 million in early 2025. The partnership aims to make breast screening more accessible globally.